How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. 

Links from this episode:  
Genentech
mAbs 

The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up to date on the newest advancements and to hear the stories that are impacting the world of biologics. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Cambridge Healthtech Institute. Innehållet i podden är skapat av Cambridge Healthtech Institute och inte av, eller tillsammans med, Poddtoppen.